FDA Panel Rejects MDMA for PTSD Treatment, Impacting Psychedelic Medicine

An FDA advisory committee has recommended against approving MDMA-assisted therapy for PTSD, citing insufficient evidence of its effectiveness and concerns over potential abuse and clinical trial misconduct. Despite promising results from Lykos Therapeutics' trials, the committee highlighted gaps in research data and the unregulated nature of the accompanying psychotherapy. The FDA will consider these recommendations in its final decision, which could significantly impact the future of psychedelic medicine.